

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com

August 20, 2014

Bombay Stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Kind Attn.: Mr. Sanjay Golecha
Mr. Gopalkrishnan

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra- Kurla Complex
Bandra – (East)
Mumbai – 400 051

Kind Attn.: Famroze Pochara
Asst. Vice President

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjra Pole,
Ahmedabad – 380 015

Re.: Press Release.

Dear Sir / Madam

We enclose herewith a copy of press release dated August 20, 2014 under the title “**Zydus receives final approval for Acyclovir Tablets**” to be released in the News Papers which gives the full details of the same.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,
FOR CADILA HEALTHCARE LIMITED



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above.

Zydus receives final approval for Acyclovir Tablets

Ahmedabad, 20 August 2014

Zydus Cadila has received the final approval from the USFDA to market Acyclovir Tablets in the strengths of 400 mg and 800 mg. The drug falls under the anti-viral segment.

The estimated sales in 2014 for Acyclovir Tablets is USD 55.8 million, as per IMS.

The group now has 95 approvals and has so far filed 249 ANDAs since the commencement of the filing process in FY 2003-04.
